Jefferies Maintains Bullish View on ARIAD Pharmaceuticals (ARIA)

Jefferies reiterated a Buy rating and $25 price target on ARIAD Pharmaceuticals (NASDAQ: ARIA) following management meetings.

The firm sees upside from here as upcoming data will help investors better assess the opportunity.

"Significant long-term upside potential lies in Iclusig line-extension (1st-line CML, GIST) and AP '113 in ALK+/EGFR-T790M NSCLC, but few expectations are priced in," analyst Eun K. Yang, Ph.D. states. "Our recent discussion with management indicates ARIA's continuing confidence in its programs; upcoming data at ASCO (5/31-6/4) and ESMO (9/27-10/1) may help better assess these programs, thus providing potential upside from here."

For an analyst ratings summary and ratings history on ARIAD Pharmaceuticals click here. For more ratings news on ARIAD Pharmaceuticals click here.

Shares of ARIAD Pharmaceuticals closed at $18.05 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Exchange Traded Concepts and ARIAM Global launch ARIA an Actively Managed ETF Led by a Portfolio Manager with a Ph.D. in AI and Computer Science
• Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy
• Jefferies upgrades Five Below to Buy, sees path to TJX-like re-rating